RHBC
CRDF icon

R.H. Bluestein & Co’s Cardiff Oncology CRDF Stock Holding History

R.H. Bluestein & Co’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-278
Closed -$90K – 309
2016
Q3 		$90K Hold
278
– – 0.01% 289
2016
Q2 		$91K Hold
278
– – 0.01% 284
2016
Q1 		$93K Hold
278
– – 0.01% 284
2015
Q4 		$108K Sell
278
-62
-18% -$24.3K 0.01% 287
2015
Q3 		$139K Sell
340
-8
-2% -$4.19K 0.01% 295
2015
Q2 		$254K Buy
+348
New +$247K 0.02% 291

Other funds holding CRDF

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

R.H. Bluestein & Co's CRDF Position: Q4 2016 in Review

R.H. Bluestein & Co sold out of Cardiff Oncology (CRDF) in Q4 2016, closing a stake of 278 shares — an estimated $90K sold.

R.H. Bluestein & Co first reported a position in CRDF in Q2 2015 and held it in 6 quarters. The position peaked at $254K in Q2 2015. 68 funds tracked by Wall St. Rank hold CRDF as of Q4 2016.

  • R.H. Bluestein & Co reported no remaining Cardiff Oncology position as of Q4 2016 after selling out during the quarter.
  • R.H. Bluestein & Co sold 278 Cardiff Oncology shares in Q4 2016, an estimated $90K.
  • R.H. Bluestein & Co first reported a position in Cardiff Oncology in Q2 2015 and held it in 6 quarters.
  • R.H. Bluestein & Co's Cardiff Oncology position peaked at $254K in Q2 2015.
  • 68 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2016.

Based on R.H. Bluestein & Co's 13F filing for Q4 2016, filed 13 Feb 2017.